Publicacións en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Cáncer (34)

2025

  1. Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors

    Molecular Cancer, Vol. 24, Núm. 1

  2. Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer

    Signal Transduction and Targeted Therapy, Vol. 10, Núm. 1

  3. Fasting and fasting-mimicking conditions in the cancer immunotherapy era

    Journal of Physiology and Biochemistry, Vol. 81, Núm. 2, pp. 383-389

  4. Genetic variants in complement-related genes: potential implications for cancer risk and progression

    Immunobiology, Vol. 230, Núm. 4

  5. Insights and perspectives into the discovery of complement-related biomarkers in cancer

    Current Opinion in Immunology, Vol. 96

  6. The C5a/C5aR1 Axis Promotes Migration of Tolerogenic Dendritic Cells to Lymph Nodes, Impairing the Anticancer Immune Response

    Cancer immunology research, Vol. 13, Núm. 3, pp. 384-399

  7. The complement system in clinical oncology: Applications, limitations and challenges

    Seminars in Immunology, Vol. 77

2024

  1. Elevated expression of complement factor I in lung cancer cells associates with shorter survival–Potentially via non-canonical mechanism

    Translational Research, Vol. 269, pp. 1-13

  2. G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1

    Cell Death and Disease, Vol. 15, Núm. 11

  3. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

    Molecular Cancer, Vol. 23, Núm. 1

2023

  1. Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer

    EMBO Reports, Vol. 24, Núm. 8

2022

  1. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d

    Frontiers in Immunology, Vol. 13

  2. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  3. Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood

    Bioengineering and Translational Medicine, Vol. 7, Núm. 3

  4. The complement system as a regulator of tumor-promoting activities mediated by myeloid-derived suppressor cells

    Cancer Letters, Vol. 549

  5. Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

    Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377

  6. Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 1

2021

  1. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer

    Translational Research, Vol. 233, pp. 77-91

  2. Molecular biomarkers in early stage lung cancer

    Translational Lung Cancer Research, Vol. 10, Núm. 2, pp. 1165-1185

  3. Surgical Outcomes in a Lung Cancer-Screening Program Using Low Dose Computed Tomography

    Archivos de Bronconeumologia, Vol. 57, Núm. 2, pp. 101-106